Cantargia Reports New Preclinical Data on Antitumor Effects of Nadunolimab in Pancreatic Cancer
LUND, SE / ACCESSWIRE / March 5, 2024 / Cantargia (STO:CANTA) (Cantargia AB);(Nasdaq Stockholm: CANTA) today reported new preclinical data...
LUND, SE / ACCESSWIRE / March 5, 2024 / Cantargia (STO:CANTA) (Cantargia AB);(Nasdaq Stockholm: CANTA) today reported new preclinical data...
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--LinusBio, a leader in precision exposome sequencing, today announced its inclusion in Fierce Medtech's "Fierce 15" list...
Company Continues to Build and Expand the Global IP Portfolio of Its One-of-a-Kind TechnologyCHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO),...
Announces 1H24 Plan for Development of Lead Candidate APVO436 for the Treatment of Frontline Acute Myeloid Leukemia, Interim Results Expected...
TORONTO, ON / ACCESSWIRE / March 5, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
BHT closes oversubscribed financing round, adds new investors to revolutionize low bone density treatmentsREDWOOD CITY, CA / ACCESSWIRE / March...
• Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans•...
Dr. Roizen to provide expertise on longevity and aging Research on aging involving Telomir’s lead product candidate focused on reversing age-related...
Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution...
BELTSVILLE, Md., March 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...
Dr. Jay Wohlgemuth, former Chief Medical & Scientific Officer of Quest Diagnostics and Dr. Ray Tabibiazar, a seasoned industry executive,...
NXP800 preliminary data update expected this month from the Phase 1b study in platinum resistant, ARID1a mutated ovarian cancer, a...
Patients with Alzheimer’s Disease show improvement in brainwaves following 4 weeks of XPro™ therapy. Boca Raton, Florida, March 05, 2024...
- Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP) - Neflamapimod...
Data support the ability of GT-02287 to prevent several steps in the disease cascade resulting from GCase misfolding and dysfunctionBETHESDA,...
NEW YORK--(BUSINESS WIRE)--#biotech--Koneksa, the evidence-based digital biomarkers company, today announced the appointment of Jessie Bakker, M.S., Ph.D., as Vice President...
SEATTLE, WA / ACCESSWIRE / March 4, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), today announced that...
Encouraging preclinical studies demonstrate potential to combine AAV-ATP7A gene therapy with CUTX-101, which could be the first FDA-approved treatment for...
-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by the End of the...
JERUSALEM, March 04, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the...